Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use

• US 5,902,603 A
• Filed: 09/13/1996
• Issued: 05/11/1999
• Est. Priority Date: 09/14/1995
• Status: Expired due to Term

• Current Assignee: Ortho-McNeil Pharmaceutical Incorporated (Johnson & Johnson)
• Original Assignee: Cygnus, Inc. (Johnson & Johnson)
• Inventors: Chen, Tung-Fen, Chiang, Chia-Ming, Jona, Janan, Ramdas, Asha, Joshi, Priti
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): Shelborne, Kathryne E.
• Application Number:
  US08/713,711
• Time in Patent Office: 970 Days
• Field of Search: 424/435, 424/447, 424/448, 424/449, 424/486, 424/DIG. 7, 604/307, 428/423.4, 514/772.3, 252/315.1
• US Class Current: 424/449
• CPC Class Codes: A61K 9/7084 Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
• CPC Class Codes: Y10S 424/07 Microporous membranes

Abstract

High capacity drug reservoirs are provided for incorporation into transdermal drug delivery systems. The drug reservoirs are hydrogels formulated from polyurethanes crosslinked with diisocyanate crosslinking agents or cured with radiation in the presence of a photoinitator. Drug loading as high as 65 to 70 wt. % or higher can be achieved by absorbing drug formulation into the reservoir after hydrogel synthesis. Methods for making and using transdermal systems containing such reservoirs are provided as well.

Claims

1. A drug reservoir for use in a transdermal drug delivery system, comprising a layer of a polyurethane hydrogel having a drug formulation comprising at least one permeation enhancer absorbed therein.

2. The drug reservoir of claim 1, containing at least about 65 wt. % drug formulation.

3. The drug reservoir of claim 1, wherein the drug is a steroid drug.

4. The drug reservoir of claim 3, wherein the steroid drug is selected from the group consisting of flurogestone acetate, hydroxyprogesterone, hydroxyprogesterone acetate, hydroxyprogesterone caproate, medroxy-progesterone acetate, norethindrone, norethindrone acetate, norethisterone, norethynodrel, desogestrel, 3-keto desogestrel, gestadene, levonorgestrel, estradiol, estradiol benzoate, estradiol valerate, estradiol cyprionate, estradiol decanoate, estradiol acetate, ethynyl estradiol, estriol, estrone, mestranol, betamethasone, betamethasone acetate, cortisone, hydrocortisone, hydrocortisone acetate, corticosterone, fluocinolone acetonide, prednisolone, prednisone, triamcinolone, aldosterone, androsterone, testosterone, methyl testosterone, and combinations thereof.

23. A method for administering a drug to a mammalian individual, comprising positioning topically on the individual a transdermal drug delivery system containing the drug reservoir of claim 1.

24. The drug reservoir of claim 1, containing at least about 40 wt. % drug formulation.

5. A transdermal drug delivery system, comprising a laminated composite of:

a high capacity drug reservoir of a polyurethane hydrogel having a drug formulation comprising at least one permeation enhancer contained therein; and

a backing layer that is substantially impermeable to the drug and which defines the upper surface of the system during drug delivery.

6. The system of claim 5, wherein the hydrogel has sufficient tack such that it serves to maintain the system in drug transmitting relationship to the body surface.

7. The system of claim 5, further including a affixing means for ensuring that the system adheres to the body surface during drug delivery.

8. The system of claim 7, wherein the affixing means comprises a layer of a pharmaceutically acceptable, pressure-sensitive contact adhesive which serves as the basal surface of the system and adheres to the body surface during drug administration.

9. The system of claim 7, wherein the affixing means comprises a peripheral ring of a pharmaceutically acceptable, pressure-sensitive contact adhesive underlying the drug reservoir.

10. The system of claim 5, wherein the drug reservoir contains at least about 40 wt. % drug formulation.

11. The system of claim 10, wherein the drug reservoir contains at least about 65 wt. % drug formulation.

12. The system of claim 8, further including a rate-controlling membrane disposed between the drug reservoir and the contact adhesive layer.

13. The system of claim 7, wherein the drug is a steroid drug.

14. The system of claim 13, wherein the steroid drug is selected from the group consisting of flurogestone acetate, hydroxyprogesterone, hydroxyprogesterone acetate, hydroxyprogesterone caproate, medroxy-progesterone acetate, norethindrone, norethindrone acetate, norethisterone, norethynodrel, desogestrel, 3-keto desogestrel, gestadene, levonorgestrel, estradiol, estradiol benzoate, estradiol valerate, estradiol cyprionate, estradiol decanoate, estradiol acetate, ethynyl estradiol, estriol, estrone, mestranol, betamethasone, betamethasone acetate, cortisone, hydrocortisone, hydrocortisone acetate, corticosterone, fluocinolone acetonide, prednisolone, prednisone, triamcinolone, aldosterone, androsterone, testosterone, methyl testosterone, and combinations thereof.

15. The system of claim 5, wherein the permeation enhancer comprises:

(a) a first component selected from the group consisting of fatty acids of the formula CH₃ (CH₂)_m COOH and fatty alcohols of the formula CH₃ (CH₂)_m CH₂ OH, where m is an integer in the range of 8 to 16;

(b) a second component comprising a fatty ester CH₃ (CH₂)_m COO!_n R in which m is an integer in the range of 8 to 16, n is 1 or 2, and R is a lower alkyl (C₁ -C₃) residue that is either unsubstituted or substituted with one or two hydroxyl groups; and

(3) a third component comprising a C₂ -C₆ alkanediol.

16. The system of claim 15, wherein the permeation enhancer comprises:

(a) a first component selected from the group consisting of fatty acids of the formula CH₃ (CH₂)_m COOH and fatty alcohols of the formula CH₃ (CH₂)_m CH₂ OH, where m is an integer in the range of 8 to 16;

(b) a second component comprising a fatty ester CH₃ (CH₂)_m COO!_n R in which m is an integer in the range of 8 to 16, n is 1 or 2, and R is a lower alkyl (C₁ -C₃) residue that is either unsubstituted or substituted with one or two hydroxyl groups; and

(3) a third component comprising a C₂ -C₆ alkanediol.

17. A method for preparing a transdermal drug delivery system having a high capacity, polyurethane hydrogel drug reservoir, comprising:

(a) reacting a polyurethane with a crosslinking agent in the presence of water, for a time period effective to form a hydrogel;

(b) absorbing a drug formulation comprising at least one permeation enhancer into the hydrogel to form a drug-containing hydrogel; and

laminating a backing layer to the hydrogel that is substantially impermeable to the drug and serves as the upper surface of the system during drug delivery.

18. The method of claim 17, wherein steps (a) and (b) are conducted simultaneously.

19. The method of claim 17, wherein step (b) is conducted subsequent to step (a).

20. The method of claim 17, wherein step (a) results in a hydrogel of sufficient tack such that it serves to maintain the system in drug transmitting relationship to the body surface.

21. The method of claim 17, further including:

step (d), providing a pharmaceutically acceptable contact adhesive as a layer immediately adjacent to the hydrogel reservoir to serve as the basal surface of the system and affix the system to the body surface during drug delivery.

22. The method of claim 17, further including:

step (d), providing a pharmaceutically acceptable contact adhesive as a peripheral ring underlying the hydrogel reservoir, to affix the system to the body surface during drug delivery.

25. A drug reservoir for use in a transdermal drug delivery system, comprising a layer of a polyurethane hydrogel having a drug formulation absorbed therein, where the drug formulation comprises an androgenic agent and a permeation enhancer.

26. The drug reservoir of claim 25 wherein the androgenic agent comprises at least one androsterone, testosterone or a derivative thereof.

27. A drug reservoir for use in a transdermal drug delivery system comprising a layer of a polyurethane hydrogel having a drug formulation absorbed therein, wherein the drug formulation comprises an androgenic agent and a permeation enhancer.